ANTITUMOUR TREATMENTCurrent options in treatment of anthracycline-resistant breast cancer
References (116)
- et al.
No evidence for the expression of a functional multidrug resistance gene product in primary human breast cancer
Ann Oncol
(1998) - et al.
Co-amplification of erb B2, topoisomeraseII, alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20
Eur J Cancer
(1993) - et al.
Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients
Eur J Cancer
(1991) - et al.
Randomized phase II study of single agent epirubicin +/– verapamil in patients with advanced metastatic breast cancer
Ann Oncol
(1993) - et al.
FAC as a second line chemotherapy in patients with metastatic breast cancer progressing under FEC
Ann Oncol
(1994) - et al.
a review
Cancer Treat Rev
(1976) Integration of chemotherapy into combined modality treatment of solid tumors
Cancer Treat Rev
(1976)- et al.
Continuous infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance (letter)
Ann Oncol
(1994) - et al.
Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus highdose folinic acid in intensively pretreated patients with metastatic breast cancer
Ann Oncol
(1996) - et al.
Vindesine in the treatment of metastatic breast cancer
Eur J Cancer
(1984)
Vinorelbine as salvage treatment for advanced breast cancer
Ann Oncol
Review of recent trial of chemotherapy for advanced breast cancer: the taxanes
Eur J Cancer
Paclitaxel and Docetaxel: Not simply two of a kind
Ann Oncol
Fixed dose short course mitomycin C with vincristine in advanced pretreated breast cancer
Ann Oncol
A phase II trial of vinorelbine and thiotepa in metastatic breast cancer
Ann Oncol
Cisplatin plus vindesine in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group
Eur J Cancer
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
Pharmac Ther
The taxoids:paclitaxel and docetaxel
Cancer Treat Rev
Paclitaxel by 3 h infusion and carboplatin in anthracycline resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group
Eur J Cancer
Paclitaxel in combination with weekly high dose 5-FU/folinic acid in the second line treatment of metastatic breast cancer
Ann Oncol
Increasing therapeutic response rate to anticancer drugs by applying the basic principles of pharmocology
Pharmacol Therapeut
Adriamycin in breast cancer: an overview of studies
Cancer Chemother Rep
A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma
Br J Cancer
The use of granulocyte colony stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer
Br J Cancer
Chemotherapy for metastatic disease
Epirubicin
Drugs
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens
Cancer
Active vs passive resistance, dose-response relationships, high-dose chemotherapy, and resistance modulation: a hypothesis
Investigational New Drugs
Overexpression of a transporter gene in a multidrug resistance human lung cancer cell line
Science
The prognostic significance of expression of the multi-drug resistance associated protein (MP) in primary breast cancer
Br J Cancer
MRP and MDR1 gene expression in primary breast carcinoma
Clinical Cancer Research
Topoisomerase II and the path of apoptosis
Contemp Oncol
Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin
Anticancer Res
Overexpression of a novel amionic transferase in multidrug resistant human breast cancer cells
J Biol Chem
Glutathione transferase GST-pi in breast tumours evaluated by three techniques
Dis Markers
Anthracycline Resistance: The problem and its current definition
Seminars in Oncology
Phase II trial of Dexverapamil in patients with non-responsive metastatic breast cancer
Br J Cancer
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial
J Clin Oncol
A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer
Cancer Chemother Pharmacol
Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continous infusion of verapamil. A phase I-II clinical trial
Med Oncol & Tumor Phrmacothr
Alteration of epirubicin pharmacokinetics and metabolism by dexverapamil: results of phase II study of patients with breast cancer patients to modulate multidrug resistance
Onkologie
The effect of cyclosporin on the pharmacokinetics of doxorubicin in patients with small lung cancer
Cancer
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline - containing chemotherapy
J Clin Oncol
A comparison of mitoxantrone and doxorubicin in breast cancer
J Clin Oncol
Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer
J Clin Oncol
Phase II study of doxorubicin versus epirubicin in advanced breast cancer
Cancer Treat Rep
Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a andomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
J Clin Oncol
Etoposide in the management of metastatic breast cancer
Cancer
Phase II study of VP16 in refractory metastatic breast cancer
Cancer Chemother Pharmacol
Clinical activity of chronic oral Etoposide in previously treated metastatic breast cancer
J Clin Oncol
Cited by (62)
AMP-activated protein kinase re-sensitizes A549 to paclitaxel via up-regulating solute carrier organic anion transporter family member 1B3 expression
2022, Cellular SignallingCitation Excerpt :PTX binds with cellular β-tubulin at the N′ terminal, then inhibits its unwinding, enhances stabilization of microtubule polymerization, destroys the dynamic balance of β-tubulin structure. As a result, PTX could block the energy transport and induce cell cycle arrest in G2/M phase, block cell mitosis, at last, induce cell apoptosis [3,6–10]. Unfortunately, the PTX resistance is frequently encountered in cancer cells, resulting in a failure of PTX treatment.
Potentialization of anticancer agents by identification of new chemosensitizers active under hypoxia
2019, Biochemical PharmacologyPluronics: Intelligent building units for targeted cancer therapy and molecular imaging
2019, International Journal of PharmaceuticsA semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro
2013, Cancer LettersCitation Excerpt :P-gp is an ATP-dependent broad-spectrum drug efflux pump, which can decrease the intracellular drug concentration, thereby reducing drug-mediated cytotoxicity. Numerous studies have confirmed the relevance of P-gp expression in clinical resistance to cancer chemotherapy [19–21]; e.g. vinblastine, vincristine, doxorubicin and paclitaxel are all affected by P-gp mediated drug resistance [22]. The β-III isotype of tubulin is usually expressed in neurons of the central and peripheral nervous systems.
Can nanomedicines kill cancer stem cells?
2013, Advanced Drug Delivery ReviewsCitation Excerpt :Even though MDR has been known for over 30 years (since discovery of Pgp in 1976) the success in overcoming it clinically is rather limited. Several strategies were proposed to overcome drug resistance [103–106]. Much effort has been devoted to development of new cytotoxic drugs and the use of combination chemotherapy regimens to improve cure rates.